Skip to content

Study · Observational study · n = 334 · 2024

3 results

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Berra C, Manfrini R, Bifari F, Cipponeri E, Ghelardi R, Centofanti L, Mortola U, Lunati E, Bucciarelli L, Cimino V, Folli F

Pharmacological research28 Nov 2024Cited by 12 (Europe PMC)

PMID39613122 (opens in a new tab)DOI10.1016/j.phrs.2024.107517 (opens in a new tab)PepBankPUB-39613122
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In obese diabetes patients, adding dulaglutide was linked to a significant HbA1c reduction from baseline after six months.

    In plain wordsIn obese diabetes patients, adding dulaglutide was linked to lower HbA1c than baseline after six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c reduction
    Study

    n = 334

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · six monthsAs given in this study (human).

    Measurements

    HbA1c reduction
    8 mmol/mol
    6 months after dulaglutide addition

    Source sentences

    Summary
    After six months of Dulaglutide treatment, we found a significant reduction in HbA1c levels (8.0+10.5 mmol/mol; p2; p<0.0001).
    4 context sentences
    Summary · context
    The study's primary endpoints were changes in: 1) HbA1c level, 2) BMI, and 3) body weight after six months of treatment.
    Summary · context
    A cohort of 583 type 2 diabetic outpatients treated with a SGLT2 inhibitor and/or other anti-diabetic medications were examined.
    Summary · context
    Because patients had suboptimal glycemic control, the GLP1-RA Dulaglutide was added to ongoing medications.
    Summary · context
    At 6 months, 334 patients had a follow-up visit.
  2. 02HumanObservational studyEfficacy outcome

    In obese diabetes patients, adding dulaglutide was linked to a significant BMI reduction from baseline after six months.

    In plain wordsIn obese diabetes patients, adding dulaglutide was linked to lower BMI than baseline after six months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody mass index reduction
    Study

    n = 334

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · six monthsAs given in this study (human).

    Measurements

    BMI reduction
    1.1 kg/m<sup>2</sup>
    6 months after dulaglutide addition

    Source sentences

    Summary
    After six months of Dulaglutide treatment, we found a significant reduction in HbA1c levels (8.0+10.5 mmol/mol; p2; p<0.0001).
    4 context sentences
    Summary · context
    The study's primary endpoints were changes in: 1) HbA1c level, 2) BMI, and 3) body weight after six months of treatment.
    Summary · context
    A cohort of 583 type 2 diabetic outpatients treated with a SGLT2 inhibitor and/or other anti-diabetic medications were examined.
    Summary · context
    Because patients had suboptimal glycemic control, the GLP1-RA Dulaglutide was added to ongoing medications.
    Summary · context
    At 6 months, 334 patients had a follow-up visit.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In obese diabetes patients, dulaglutide efficacy did not differ by cardiovascular risk category, age, or diabetes duration.

    In plain wordsIn obese diabetes patients, dulaglutide efficacy did not differ by cardiovascular risk category, age, or diabetes duration.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeEfficacy across baseline subgroups
    Study

    n = 334

    Comparator
    Different cardiovascular risk categories
    Analysis
    Secondary
    Outcome group
    Overall treatment effect · Metabolic and weight

    Source sentences

    Summary
    Efficacy of Dulaglutide was not affected by different CVD risk categories, age and T2DM duration.
    4 context sentences
    Summary · context
    Secondary endpoints were evaluation of Dulaglutide addition in type 2 diabetic patients: 1) with more or less than ten years of T2DM; 2) more or less than 75 years of age and in different subgroups of CVR.
    Summary · context
    A cohort of 583 type 2 diabetic outpatients treated with a SGLT2 inhibitor and/or other anti-diabetic medications were examined.
    Summary · context
    Because patients had suboptimal glycemic control, the GLP1-RA Dulaglutide was added to ongoing medications.
    Summary · context
    At 6 months, 334 patients had a follow-up visit.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.